<DOC>
	<DOCNO>NCT01927939</DOCNO>
	<brief_summary>This study evaluate effectiveness 18F-FDG PET follow metastastic bone lesion predict outcome breast cancer patient therapy . Primary outcome : Using 18F-FDG uptake evaluate metastatic bone status treatment . The PET result compare result Tc-99m MDP bone scintigraphy . Secondary outcome : Evaluate relationship 18F-FDG uptake metastatic bone lesion ( 1 ) breast cancer relate tumor marker , ( 2 ) patient ' survival .</brief_summary>
	<brief_title>18F-FDG PET Metabolic Phenotype Evaluating Therapeutic Response Breast Cancer Patients With Bone Metastases .</brief_title>
	<detailed_description>Background : Although 99mTc MDP bone scintigraphy sensitive tool screen metastatic bone status , satisfactory image modality evaluate residual disease therapy . 18F-FDG PET effective image tool many malignancy include breast cancer , diagnosis staging , also monitor response follow disease status therapy . Purpose : This study evaluate effectiveness 18F-FDG PET follow metastastic bone lesion predict outcome breast cancer patient therapy . Method : Breast cancer patient bone metastasis , age 20-90 year-old , include study . Primary outcome : Using 18F-FDG uptake evaluate metastatic bone status treatment . The PET result compare result Tc-99m MDP bone scintigraphy . Secondary outcome : Evaluate relationship 18F-FDG uptake metastatic bone lesion ( 1 ) breast cancer relate tumor marker , ( 2 ) patient ' survival .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>1 . Ageï¼š2090 year old 2 . Histological proven breast cancer , know metastatic bone lesion ( ) 3. write informed consent sign 1. pregnant intend pregnant 2. malignancy know</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Breast cancer ; bone metastases ; 18F-FDG PET ; 99mTc bone scintigraphy ; therapy response monitoring ; prognosis</keyword>
</DOC>